Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML

References

• Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451–64
   PubMed Web of Science ®Google Scholar
• Druker BJ. Imatinib as a paradigm of targeted therapies. J Clin Oncol 2003; 21: 239S–45S
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon (plus cytarabine in newly diagnosed chronic myeloid leukemia. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. N Engl J Med 2003; 349: 1423–32
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–80
   PubMed Web of Science ®Google Scholar
• Kolb H-J, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–50
   PubMed Web of Science ®Google Scholar
• Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–44
   PubMed Web of Science ®Google Scholar
• Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133–42
   PubMed Web of Science ®Google Scholar
• Dietz AB, Bulur PA, Erickson MR, et al. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells. J Hematotherapy Stem Cell Res 2000; 9: 95–101
   PubMedGoogle Scholar
• Dietz AB, Padley DJ, Butler GW, et al. Clinical–grade manufacturing of dendritic cells from CD14+ precursors: experience from phase 1 clinical trial in chronic myelogenous leukemia and malignant melanoma. Cytotherapy 2004; 6: 563–70
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135–42
   PubMed Web of Science ®Google Scholar
• Buno I., Wyatt W. A., Zinsmeister, et al. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 1998; 92: 2315–21
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001; 93: 243–51
   PubMed Web of Science ®Google Scholar
• Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969–76
   PubMed Web of Science ®Google Scholar
• Kurbegov D, Molldrem JJ. Immunity to chronic myelogenous leukemia. Hematol Oncol Clin N Am 2004; 18: 733–52
   PubMedGoogle Scholar
• Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037–42
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood 2004; 104: 77A
   Google Scholar
• Dong R, Cwynarski K, Entwistle A, et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 2003; 101: 3560–7
   PubMedGoogle Scholar
• Eisendle K, Lang A, Eibl B, et al. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br J Haematol 2003; 120: 63–73
   PubMedGoogle Scholar
• Figdor CG, de Vries IJM, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nature Med 2004; 10: 475–80
   PubMed Web of Science ®Google Scholar
• Lissoni P, Malugani F, Bonfanti A, et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regulators Homeostatic Agents 2001; 15: 140–4
   PubMed Web of Science ®Google Scholar
• Dietz AB, Souan L, Knutson GJ, et al. IM inhibits proliferation of T cells in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–9
   PubMed Web of Science ®Google Scholar